top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Dental Endodontics Market Size to Explore Emerging Trends of Coming Years

0 votes
3 views

Endodontic is a specialized branch of dentistry dealing with diagnosis and treatment of impairments related to tooth root, dental pulp, and surrounding tissues. Endodontic treatments include procedures such as fixing broken teeth, root canal therapy, and dental trauma. Root canal treatment is considered to be a major part of endodontic. Majority of patients undergoing a root canal treatment fall in the age group of 40 years to 60 years. According to W.H.O data, India and China that constitute two-thirds of the world population will have more than 10% of their population in this age bracket by 2020 and such a fact will fuel the future growth of the global endodontic market.

Report overview @ https://www.transparencymarketresearch.com/endodontic-supplies-market.html

Regenerative endodontic is an alternative to traditional surgical method, is a major breakthrough in the endodontic field. It is a natural process used by endodontists to grow tissues in order to replace the traumatized or infected pulp; however, the market is expected to experience a sluggish growth during the forecast period due the risks involved in restoration of core build ups and possibilities of infection arising from the remaining part of the tooth. Rise in dental tourism, rapidly growing geriatric population, and introduction of government initiates and dental treatment packages are some of the key divers of the global endodontic supplies market.

The global endodontic supplies market has been segmented based on product type, application, and region. In terms of product type, the market is categorized into endodontic files, obturation, and permanent endodontic sealers. Endodontic files accounted for the largest market segment in 2011 holding nearly 47.1% of the market share. The market share is expected to grow during the forecast period. Endodontic files are metallic instruments used in dentistry. Length of the files available in the market include 21mm, 25mm, and 31mm. Improvement in technology and demand from baby boomers is expected to drive the growth of the endodontic files segment.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32294

The baby boomers have strong teeth but weak gingival tissues, which lead to acute sensitivity and tooth decay. Root canal treatment is a safe and low-cost method to treat the tooth pulp while retaining the tooth for a longer period of time. Introduction of highly tensile Ni-Ti endodontic file that are able to shape the root canals without any distortion, has helped the market to grow. The possibility of endodontic files breaking and causing root canal infection could hinder the growth of the market.

Obturation is the process of filling root canals and the associated pulp chamber with inert filling elements such as a eugenol-based cement or gutta percha. The demand for obturation materials is directly proportional to the increase in cases leading to root canal treatment; however, the advent of modern technologies such as surgery and the fear of infection caused by root canal treatment can hinder the growth of obturation market globally.

The global obturation market is further classified into single use and delivery systems, according to product types. Both the products have approximately equal shares in the market. Permanent endodontic sealers are materials used to seal the traumatized root canal by sticking to the gutta percha borders and root canal walls. Its water insoluble property helps in minimizing the risks of root canal treatment failure. The calcium hydroxide present in permanent endodontic sealers help in rapid periodical healing. Demand for permanent endodontic sealers owing to the desire to retain the tooth for a longer period and avoid dental surgery. However, a fall in demand for root canal treatments and successive rise in demand for modern technological methods such as various types of surgeries has led to a sluggish growth of the permanent endodontic sealers segment.

Pre Book Endodontic Supplies Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=32294&ltype=S

Based on application, the market has been classified into hospitals and dental clinics. In terms of geography, the global endodontic supplies market in categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific holds the largest market owing to its large population.

Key players of the global endodontic supplies market include DMG Chemisch-Pharmazeutische Fabrik GmbH, Brasseler USA, DiaDent, DMG America, Septodont, VOCO GmbH, Ivoclar Vivadent AG, and DENTSPLY International, Inc.

More Trending Reports by Transparency Market Research –

Single-Cell Analysis Market: globenewswire.com/news-release/2019/05/20/1828056/0/en/Single-Cell-Analysis-Market-to-rise-at-a-healthy-15-4-CAGR-till-2025-Consumables-Segment-Held-Dominant-Share-TMR.html

Antimicrobial Susceptibility Test Market: globenewswire.com/news-release/2019/07/18/1884570/0/en/Antimicrobial-Susceptibility-Test-Market-to-generate-US-3-814-0-million-revenue-by-2025-Noted-TMR.html

posted Feb 13 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Transparency Market Research (TMR) has published a new report titled, “Psoriatic Arthritis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global psoriatic arthritis therapeutics market was valued at US$ 6,011.7 Mn in 2017. It is projected to expand at a CAGR of 11.4% from 2018 to 2026. High prevalence of psoriatic arthritis, large unmet medical needs, and new product approvals are anticipated to drive the global market in the next few years.

North America is expected to dominate the global psoriatic arthritis therapeutics market during the forecast period, followed by Europe. Potential unmet medical needs for moderate to severe psoriatic arthritis, increase in adoption of biologic drugs, and approvals of new therapeutic drug classes in the U.S. and Europe are likely to drive the psoriatic arthritis therapeutics market in these regions during the forecast period. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period. 

High prevalence and increase in incidence rate of psoriatic arthritis to drive market

High prevalence and rise in incidence rate of psoriatic arthritis across the globe is a key factor driving the global psoriatic arthritis therapeutics market. Chances of developing psoriatic arthritis among patients with psoriasis is high, and the number of patients with psoriatic arthritis has been increasing significantly in the last few years. According to the International Federation of Psoriasis Association, more than 125 million people were affected with psoriasis, globally, in 2015. It is estimated that between 10% and 30% of patients with psoriasis tend to develop psoriatic arthritis.

According to the study published in the Journal of the American Academy of Dermatology, in 2013, Denmark had the highest prevalence rate of psoriatic arthritis, with around 42% prevalence rate, while the lowest prevalence rates were recorded in Canada and Belgium. Thus, the high prevalence and substantial rise in incidence rate of psoriasis and psoriasis-led psoriatic arthritis across globe is a key factor driving the global psoriatic arthritis therapeutics market.

Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=61917

Interleukin inhibitors and PDE4 inhibitors drugs to propel the psoriatic arthritis therapeutics market

The report offers a detailed segmentation of the global psoriatic arthritis therapeutics market based on different therapeutic drug classes approved and commercialized for psoriatic arthritis. Based on drug class, the global market has been segmented into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. Interleukin inhibitors drugs have evolved as new therapeutic drug class for the treatment of psoriatic arthritis when other therapeutic drugs classes, especially TNF alpha inhibitors, fail to relieve the symptoms of psoriatic arthritis.

Interleukin inhibitor drugs, especially IL-17A inhibitor drugs, have shown the highest clinical efficacy, as compared to any other biologic drug available, to relive the symptoms of psoriatic arthritis. Interleukin inhibitors have been recently approved for the treatment of psoriatic arthritis and are increasingly gaining popularity among physicians across the globe. Currently, only four interleukin inhibitors ? Cosentyx (Secukinumab), Stelara (USTEKINUMAB), Tremfya (Guselkumab) and Taltz (Ixekizumab) ? have been approved for the treatment of psoriatic arthritis.

Interleukin inhibitors drug sales are estimated to rise about four times by the end of 2026. PDE4 inhibitor is the new therapeutic drug that was approved by the USFDA, in March 2014, for the treatment of psoriatic arthritis. Currently, Otezla (Apremilast) is the only approved PDE4 inhibitor drug for psoriatic arthritis treatment. Within one year of launch, Otezla generated a sale of more than US$ 1 Billion in the year 2016. 

Parenteral route of administration to dominate global market

In terms of route of administration, the global psoriatic arthritis therapeutics market has been segmented into oral route, parenteral route, and topical routes. The parenteral route segment dominated the global market in 2017. It is likely to maintain its dominance by the end of 2026. Majority of the therapeutic drugs available for the treatment of moderate to severe psoriatic arthritis are biologics drugs that are administered through the subcutaneous and intravenous routes. The high cost and large volume prescription of biologic drugs contributed to the leading share held by the parenteral route segment in 2017.

Buy Now Psoriatic Arthritis Therapeutics Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=61917&ltype=S

Hospital pharmacies segment to account for high market share

In terms of distribution channel, the global psoriatic arthritis therapeutics market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to account for a significant share of the market by 2026. Rise in the number of hospital admissions of patients with psoriatic arthritis and high cost of treatment are anticipated to contribute to the high share of the segment by the end of 2026. Promising biologic product pipeline of leading biopharmaceutical companies is likely to receive approval and commercialization in the near future. Biologic drugs are most commonly and easily available at hospital pharmacy stores. Hence, expected launch and commercialization of biologic therapeutic drugs is likely to drive the hospital pharmacies segment during the forecast period.

Asia Pacific offers high incremental opportunity

The psoriatic arthritis therapeutics market in Asia Pacific is projected to expand at a high CAGR during the forecast period. High prevalence of psoriatic arthritis in highly populated countries, such as China and India, rapidly improvement in health care infrastructure, increase in access to health care facilities, and rise in per capita health care expenditure in the region are likely to fuel the market in Asia Pacific during the forecast period. Large base of pharmaceutical companies in countries such as India, Japan, and China also drives the market in the region. High demand and increased adoption of biologic drugs in developed markets, such as Australia & New Zealand, are projected to propel the psoriatic arthritis therapeutics market in Asia Pacific. For instance, in Australia, the number of patients with severe psoriasis receiving treatment under the Pharmaceutical Benefit Scheme (PBS) with biologics has increased by more than 60% between 2014 and 2016.

Key trend of M&A among leading players to diversify and strengthen psoriatic arthritis product portfolio

The global psoriatic arthritis therapeutics market is highly consolidated, with a few global players accounting for a major share in respective regions. Leading players in psoriatic arthritis therapeutics are engaged in mergers, acquisitions, and strategic collaborations to broaden their psoriatic arthritis therapeutics portfolio. For instance, more than 20 mergers, acquisitions, and strategic collaborations have taken place between 2014 and 2018. Most biopharmaceutical companies have invested significantly in clinical R&D for the development of psoriatic arthritis therapeutics products. Key players operating in the psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company. 

More Trending Reports by Transparency Market Research –

Shock Wave Therapy Device Market: prnewswire.com/news-releases/shock-wave-therapy-device-market-to-reach-us-1399-mn-by-2025-orthopedic-and-urology-application-leads-the-market-677627753.html

Life Sciences BPO Market: prnewswire.com/news-releases/life-sciences-bpo-market-is-expected-to-touch-us286-3-billion-by-2023—says-tmr-300813081.html

0 votes

Non-opioid Pain Treatment Market: Introduction

  • Pain management is an important component of the medical care. Common types of chronic pain conditions are migraine, lower back pain, osteoarthritis, fibromyalgia, localized musculoskeletal pain, and localized neuropathic pain. While opioids may be appropriate for addressing acute or chronic pain relating to palliative or end-of-life care, and active cancer treatment, other non-opioid pain management options are available to treat chronic pain.
  • Evidences show that non-opioid medications and non-pharmacologic interventions can be effective in treating common types of chronic pain and are considered safer than opioids.

Report Overview @ https://www.transparencymarketresearch.com/non-opioid-pain-treatment-market.html

Key Drivers and Restraints of Global Non-opioid Pain Treatment Market

  • The global non-opioid pain treatment market is driven by increasing easy and effective medications of non-opioids drugs for pain treatment, and also their less side-effects and low cost for some treatments
  • Opioids have several disadvantages, such as risk of nausea and vomiting, somnolence, androgen deficiency, respiratory depression, constipation, physical dependence, and tolerance. Opioid medications also carry a risk of abuse or addiction by either the patient or non-medical users. For these reasons, consideration of non-opioid strategies for pain management is beneficial. This is fueling the growth of the global non-opoid pain treatment market.
  • Better healthcare facilities and availability of sophisticated and novel treatment options, and increasing research and developmental activities related to non-opoid treatment for pain relief are the major factors propelling the growth of the non-opoid pain treatment market

Get a Glimpse of the In-Depth Analysis through our Comprehensive “Non-opioid Pain Treatment Market” Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74676

  • Increasing geriatric population and rising prevalence of diseases, such as arthritis, cancer, epilepsy, dental disorders, etc., leading to chronic pain conditions, such as,  migraine, lower back pain, osteoarthritis, fibromyalgia, localized musculoskeletal pain, and localized neuropathic pain, are fueling the growth of the global non-opioid pain treatment market
  • Preference for alternative therapies and fake products, however, are anticipated to restrain the growth of the global non-opioid pain treatment market

Strategies Adopted by Key Players to Offer Attractive Opportunities

  • Companies operating in the global non-opioid pain treatment market focus on addressing the needs of the medical communities and patient population by developing effective and novel products. Leading players are engaging in strategies, such as acquisitions, mergers, and collaborations, along with research and developmental activities to strengthen their position in the global market.
  • In June 2019, Ironwood Pharmaceuticals and Allergan initiated patient dosing in Phase II Clinical Trial of MD-7246 in patients with abdominal pain associated with IBS-D
  • In January 2018, Centrexion Therapeutics raised US$ 67 million and launched Phase 3 program for CNTX-4975 in knee osteoarthritis pain. CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin for the treatment of chronic pain due to knee osteoarthritis. CNTX-4975 is a highly differentiated, novel, non-opioid therapy designed to be injected directly into the painful joint.
  • In June 2018, Sandoz Canada announced that it had finalized its collaboration agreement with Tilray, a Health Canada licensed producer of medical cannabis, allowing Sandoz Canada to become the first Canadian pharmaceutical company to enter the medical cannabis field
  • Emerging economies present lucrative opportunities in the non-opioid pain treatment market due to increase in patient population and rise in initiatives by governments in the health care sector.

Pre Book “Non-opioid Pain Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=74676&ltype=S

North America to Account for Major Share of Global Non-opioid Pain Treatment Market

  • North America is projected to capture leading share of the global non-opioid pain treatment market due to health awareness, rise in patient population, a well-established health care infrastructure, increasing research and developmental activities,  and presence of key players in the region
  • The non-opioid pain treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to rise in patient population, increase in initiatives by governments in the health care sector, surge in incidences of diseases, such as arthritis, cancer, dental disorders, etc., increase in geriatric population, and rise in interest of key players in expanding into the region

Key Players Operating in Global Non-opioid Pain Treatment Market

Leading players in the global non-opioid pain treatment market are focusing on research and development activities. Companies are adopting various growth strategies, including mergers, acquisitions, product upgrades, product launches & approvals, partnerships, and collaborations. Leading players operating in the global non-opioid pain treatment market are:

  • Allergan
  • Aphria Inc.
  • Bedrocan
  • Cara Therapeutics
  • Centrexion Therapeutics
  • Medical Marijuana, Inc.
  • Medropharm GmbH
  • Panag Pharma Inc.
  • Tilray

More Trending Reports by Transparency Market Research –

ePharmacy Market: prnewswire.com/news-releases/epharmacy-market-to-reach-us128-billion-by-2023-transparency-market-research-560938961.html

Canada Home Healthcare Market: prnewswire.com/news-releases/canada-home-healthcare-market-set-to-reach-us1894-bn-by-the-end-of-2020-transparency-market-research-565741581.html

0 votes

The global dental endodontics market can be termed as a consolidated market with a healthy level of competition among the major players as two leading players holds more than 50% of the global market, states a new market research report by Transparency Market Research. On the other hand, the consumables segment is extremely fragmented in nature with a presence of a large number of regional and international players. Some of the leading players operating in the dental endodontics are Henry Schein, Inc., Coltene Holding AG, Septodont Holding, Peter Brasseler Holdings, FKG Dentaire S.A., Ivoclar Vivadent, Dentsply Sirona, Ultradent Products Inc, Mani, Inc, Danaher Corporation, and L.P. These players are focusing on technological advancements and innovations, which is estimated to encourage the overall growth of the global market throughout the forecast period.

According to the market research report by Transparency Market Research, in 2016, the global market for dental endodontics was worth US$1.1 bn and is predicted to reach a value of US$1.7 bn by the end of 2025. The market is estimated to register a healthy 5.20% CAGR between 2017 and 2025.

Request Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=38438

Development of Healthcare Infrastructure to Drive Asia Pacific Market

From a regional perspective, Europe is expected to lead the global dental endodontics market and account for a large share throughout the forecast period. This region is estimated to be followed by North America. On the other hand, Asia Pacific is estimated to offer potential growth opportunities for the market players in the next few years. The increasing awareness among consumers regarding the dental health and the improving healthcare infrastructure are the major factors that are predicted to accelerate the growth of the Asia Pacific market throughout the forecast period. Furthermore, the rapid development of the medical tourism industry and technological developments in this field are some of the other factors that are estimated to accelerate the growth of the dental endodontics market in Asia Pacific in the near future.

Furthermore, on the basis of product type, the global market for dental endodontics market has been categorized into instruments and consumables. In 2016, the consumables segment accounted for more than 70% of the global market and is predicted to continue with its dominance throughout the forecast period. The high growth of this segment can be attributed to the increasing use of fresh consumables during the treatment procedures of endodontics.

Request Brochure @ 

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=38438

Rising Prevalence of Dental Infections to Encourage Market Growth

The global dental endodontics market is projected to grow at a healthy rate in the next few years. The rising geriatric population and the increasing prevalence of dental infections, owing to the changing eating habits are the key factors that are estimated to encourage the growth of the global dental endodontics market in the next few years. In addition to this, a significant rise in the incidence of accidents and a rise in the prevalence of dental ailments are further projected to accelerate the growth of the overall market throughout the forecast period.

Furthermore, the rapid development of the dental tourism, especially in developing economies, such as India, Hungary, Mexico, and China is projected to accelerate the growth of the global endodontics market in the next few years. On the flip side, the high cost of the dental procedures and the strict regulations related to the manufacturing and approval of advanced innovative procedures are some of the key factors that are predicted to restrict the growth of the overall market in the near future.

0 votes

The vendor landscape of the global non-small cell lung cancer therapeutics market features the presence of a number of players, but was dominated by Genentech, a Roche company, which accounted for nearly 36% of the overall market in 2014, observes a recent report by Transparency Market Research (TMR). The market is marked with a moderate level of competition and focus on the development of new and more effective varieties of drugs has increased from companies anticipating a better grip on the market. Strategic collaborations with the view of expanding geographical outreach and product portfolios is also a key strategy adopted by companies operating in the global non-small cell lung cancer therapeutics.

Some of the leading companies operating in the market are Novartis AG, Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Pfizer, Inc., Boehringer Ingelheim, and Eli Lilly and Company.

According to the report, the global non-small cell lung cancer therapeutics market will rise to a valuation of US$15.1 bn by 2023.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Asia Pacific Promising Excellent Growth Opportunities

Geographically, the market in Asia Pacific is expected to emerge as one of the leading contributors of revenue to the global market, thanks to the rising awareness regarding cancer and the active role of governments in the region in supporting the treatment of lung cancer through subsidized treatment and medicines in public healthcare centers. The region will continue to remain one of the most lucrative regional market for the field of non-small cell lung cancer therapeutics owing to the rising prevalence of lung cancer.

Based on drugs, the segment of angiogenesis inhibitors is expected to dominate in terms of demand as well as revenue contribution to the global market. This can be attributed to its effectiveness and the increased adoption of targeted therapies in a number of regional markets. The segment is expected to rise to a valuation of US$2,020.4 mn by 2023.

Rich Pipeline of Drugs and Continuous R&D Efforts Open Up Promising Growth Avenues for Market

The rising prevalence of lung cancer globally is naturally the leading cause driving the market for non-small cell lung cancer therapeutics. The increased understanding regarding the various changes observed in non-small cell lung cancer cells that help them further grow is leading to the development of newer drug classes for targeting the changes specifically. Active R&D efforts in this field are also proving beneficial for the overall development of the global non-small cell lung cancer therapeutics market.

Buy Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=504&ltype=S

Thanks to continuous efforts and continuous influx of funds into R&D from market players, the market has seen the development of a rich pipeline of innovative drug classes in the past few years. Innovative new generation drugs such as Alecensa (alectinib), which is development by Genentech for the treatment of ALK-positive non-small cell lung cancer, are being approved by a number of drug approval bodies for marketing across the globe. This scenario has also helped a number of new players foray into the market, thus improving the market’s growth prospects.

However, as several highly anticipated drugs are still in the early stages of pipeline, which may take some more time to hit the market, there is a level of uncertainty regarding returns on investment. Moreover, resistance of several cancers to targeted therapies also poses challenges to the further expansion of the market to a certain degree.

0 votes

The global dental consumables market is anticipated in a report by Transparency Market Research (TMR) to find top players accounting for a larger share. Leading companies secured close to a 62.0% share of the market in a recent year. Owing to their excellent brand recognition and low pricing, Danaher Corporation, Henry Schein Inc., and Dentsply Sirona have managed to keep ahead of their competitors. With a view to strengthen their presence in the market, these companies are expected to continue to take part in joint ventures, takeovers, and mergers.

TMR prognosticates the global dental consumables market to grow strong at a 6.1% CAGR for the forecast tenure 2016-2024 to earn a US$33.4 bn by the end of 2024. By product, crowns and bridges could take hold of a greater share of the market while rising at a 7.2% CAGR. Regionally, the market is predicted to witness the rise of Europe as a frontrunner collecting a 41.1% share.

Want to know the obstructions to your company’s growth in future? Request a PDF sample here

Affordable Oral Healthcare Services in Emerging Countries Increase Uptake

Over the course of last few years, demand for dental consumables is envisaged to increase on the back of dental tourism in India, Turkey, and Hungary and the emergence of new services. A number of customers are being attracted to adopt dental treatments due to the less expensive nature of oral healthcare services offered in developing countries. Other factors that could work in the favor of the market are minimal government intervention in the operation of healthcare firms in developing economies, availability of improved treatment methods, and low labor cost.

Overall growth of the global dental consumables market is foreseen to gain impetus as a result of the rising success rate of dental implants, especially for upper jaw treatments. This has given rise to the adoption of various types of procedures that involve dental implants. Sophisticated healthcare facilities in European countries such as Italy, Spain, the U.K., and Greece are projected to support the growth of the market.

To Know the Segments Analyzed in the Dental Consumables Market Report, Ask for a Brochure here

Heavy Research and Development Spending Increases Cost of Dental Consumables

Large spending on research and development activities could act as a leading growth restraint for the global dental consumables market. This has resulted into expensive costing of products offered in the market. On the other hand, poor reimbursement policies are foretold to hamper the demand for dental consumables in the coming years.

However, the global dental consumables market is projected to create lucrative prospects while riding on the rising prevalence of dental diseases such as tooth erosion, mouth sores, tooth decay, and gum decay. While this could benefit the market, there could be rewarding growth opportunities taking birth due to increasing incidence of chronic diseases. Furthermore, growing attention toward oral care, changing lifestyle, and improving disposable income are envisioned to increase the demand in the market.

...